ALX Oncology Executive Compensation Details Revealed
Ticker: ALXO · Form: DEF 14A · Filed: Apr 21, 2025 · CIK: 1810182
Sentiment: neutral
Topics: executive-compensation, proxy-statement, equity-awards
Related Tickers: ALXO
TL;DR
ALXO proxy shows exec comp details for 2022-2024, focusing on equity awards for Pons & Lettmann.
AI Summary
ALX Oncology Holdings Inc. filed a DEF 14A on April 21, 2025, detailing executive compensation for the fiscal years ending December 31, 2022, 2023, and 2024. The filing includes information on equity awards granted to Named Executive Officers (NEOs) such as Jaume Pons and Jason Lettmann, including their year-end fair values and changes in fair value for outstanding and unvested awards.
Why It Matters
This filing provides transparency into how ALX Oncology compensates its top executives, which can influence investor perception and the company's ability to attract and retain talent.
Risk Assessment
Risk Level: low — This is a routine DEF 14A filing providing information on executive compensation and does not indicate any immediate operational or financial risks.
Key Numbers
- 2022-2024 — Fiscal Years Covered (Executive compensation data for these years is detailed.)
Key Players & Entities
- ALX Oncology Holdings Inc. (company) — Filer
- Jaume Pons (person) — Named Executive Officer
- Jason Lettmann (person) — Named Executive Officer
- 0000950170-25-056291 (filing_id) — Accession Number
FAQ
What is the primary purpose of this DEF 14A filing?
The primary purpose is to provide detailed information regarding the compensation of the company's named executive officers and other related corporate governance matters.
Who are the Named Executive Officers (NEOs) mentioned in relation to equity awards?
Jaume Pons and Jason Lettmann are mentioned as NEOs in the context of equity awards.
What specific types of compensation are detailed for the NEOs?
The filing details equity awards, including their year-end fair value for outstanding and unvested awards, and changes in fair value.
What is the fiscal year end for ALX Oncology Holdings Inc.?
The fiscal year end for ALX Oncology Holdings Inc. is December 31st.
When was this DEF 14A filing submitted?
This DEF 14A filing was submitted on April 21, 2025.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 21, 2025 by Jaume Pons regarding ALX ONCOLOGY HOLDINGS INC (ALXO).